Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease.

Martin WP, Vaughan LE, Yoshida K, Takahashi N, Edwards ME, Metzger A, Senum SR, Masyuk TV, LaRusso NF, Griffin MD, El-Zoghby Z, Harris PC, Kremers WK, Nagorney DM, Kamath PS, Torres VE, Hogan MC.

Mayo Clin Proc Innov Qual Outcomes. 2019 May 27;3(2):149-159. doi: 10.1016/j.mayocpiqo.2019.03.004. eCollection 2019 Jun.

2.

International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people.

Gimpel C, Bergmann C, Bockenhauer D, Breysem L, Cadnapaphornchai MA, Cetiner M, Dudley J, Emma F, Konrad M, Harris T, Harris PC, König J, Liebau MC, Marlais M, Mekahli D, Metcalfe AM, Oh J, Perrone RD, Sinha MD, Titieni A, Torra R, Weber S, Winyard PJD, Schaefer F.

Nat Rev Nephrol. 2019 May 22. doi: 10.1038/s41581-019-0155-2. [Epub ahead of print] Review.

PMID:
31118499
3.

Pancreatic Cysts and Intraductal Papillary Mucinous Neoplasm in Autosomal Dominant Polycystic Kidney Disease.

McNicholas BA, Kotaro Y, Martin W, Sharma A, Kamath PS, Edwards ME, Kremers WK, Chari ST, Torres VE, Harris PC, Takahashi N, Hogan MC.

Pancreas. 2019 May/Jun;48(5):698-705. doi: 10.1097/MPA.0000000000001306.

PMID:
31091218
4.

Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease.

Bae KT, Zhou W, Shen C, Landsittel DP, Wu Z, Tao C, Chapman AB, Torres VE, Yu ASL, Mrug M, Bennett WM, Harris PC; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):823-833. doi: 10.2215/CJN.10360818. Epub 2019 May 14.

PMID:
31088850
5.

Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.

Yu ASL, Shen C, Landsittel DP, Grantham JJ, Cook LT, Torres VE, Chapman AB, Bae KT, Mrug M, Harris PC, Rahbari-Oskoui FF, Shi T, Bennett WM; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2019 May;95(5):1253-1261. doi: 10.1016/j.kint.2018.12.023. Epub 2019 Mar 4.

PMID:
30922668
6.

PKD1 Duplicated regions limit clinical Utility of Whole Exome Sequencing for Genetic Diagnosis of Autosomal Dominant Polycystic Kidney Disease.

Ali H, Al-Mulla F, Hussain N, Naim M, Asbeutah AM, AlSahow A, Abu-Farha M, Abubaker J, Al Madhoun A, Ahmad S, Harris PC.

Sci Rep. 2019 Mar 11;9(1):4141. doi: 10.1038/s41598-019-40761-w.

7.

Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts.

Beara-Lasic L, Cogal A, Mara K, Enders F, Mehta RA, Haskic Z, Furth SL, Trachtman H, Scheinman SJ, Milliner DS, Goldfarb DS, Harris PC, Lieske JC; investigators of the Rare Kidney Stone Consortium.

Pediatr Nephrol. 2019 Mar 10. doi: 10.1007/s00467-019-04210-0. [Epub ahead of print]

PMID:
30852663
8.

Multiple unilateral subcapsular cortical hemorrhagic cystic disease of the kidney: CT and MRI findings and clinical characteristic.

Yoshida K, Takahashi N, King BF, Kawashima A, Harris PC, Cornell LD, Cornec-Le Gall E, Inoue D, Mizushima I, Kawano M, Thervet E, de Cotret PR, Torres VE.

Eur Radiol. 2019 Feb 26. doi: 10.1007/s00330-019-06057-3. [Epub ahead of print]

PMID:
30806804
9.

Development of a simple numerical model for trabecular bone structures.

Peña-Solórzano CA, Albrecht DW, Paganin DM, Harris PC, Hall CJ, Bassed RB, Dimmock MR.

Med Phys. 2019 Apr;46(4):1766-1776. doi: 10.1002/mp.13435. Epub 2019 Mar 5.

PMID:
30740701
10.

Progress in the understanding of polycystic kidney disease.

Torres VE, Harris PC.

Nat Rev Nephrol. 2019 Feb;15(2):70-72. doi: 10.1038/s41581-018-0108-1. No abstract available.

11.

Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.

McKenzie KA, El Ters M, Torres VE, Harris PC, Chapman AB, Mrug M, Rahbari-Oskoui FF, Bae KT, Landsittel DP, Bennett WM, Yu ASL, Mahnken JD.

BMC Nephrol. 2018 Dec 27;19(1):378. doi: 10.1186/s12882-018-1182-0.

12.

Polycystic kidney disease.

Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE.

Nat Rev Dis Primers. 2018 Dec 6;4(1):50. doi: 10.1038/s41572-018-0047-y. Review.

PMID:
30523303
13.

Recent advances in the identification and management of inherited hyperoxalurias.

Sas DJ, Harris PC, Milliner DS.

Urolithiasis. 2019 Feb;47(1):79-89. doi: 10.1007/s00240-018-1093-3. Epub 2018 Dec 10. Review.

PMID:
30535828
14.

Population data improves variant interpretation in autosomal dominant polycystic kidney disease.

Mallawaarachchi AC, Furlong TJ, Shine J, Harris PC, Cowley MJ.

Genet Med. 2019 Jun;21(6):1425-1434. doi: 10.1038/s41436-018-0324-x. Epub 2018 Oct 29.

PMID:
30369598
15.

CD8+ T cells modulate autosomal dominant polycystic kidney disease progression.

Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K.

Kidney Int. 2018 Dec;94(6):1127-1140. doi: 10.1016/j.kint.2018.06.025. Epub 2018 Sep 21.

16.

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE.

J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18.

PMID:
30228150
17.

Effect of external fixation rod coupling in computed tomography.

Peña-Solórzano CA, Dimmock MR, Albrecht DW, Paganin DM, Bassed RB, Klein M, Harris PC.

Strategies Trauma Limb Reconstr. 2018 Nov;13(3):137-149. doi: 10.1007/s11751-018-0318-x. Epub 2018 Sep 15.

18.

Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing.

Lanktree MB, Haghighi A, Guiard E, Iliuta IA, Song X, Harris PC, Paterson AD, Pei Y.

J Am Soc Nephrol. 2018 Oct;29(10):2593-2600. doi: 10.1681/ASN.2018050493. Epub 2018 Aug 22.

PMID:
30135240
19.

Characterization of three ciliopathy pedigrees expands the phenotype associated with biallelic C2CD3 variants.

Boczek NJ, Hopp K, Benoit L, Kraft D, Cousin MA, Blackburn PR, Madsen CD, Oliver GR, Nair AA, Na J, Bianchi DW, Beek G, Harris PC, Pichurin P, Klee EW.

Eur J Hum Genet. 2018 Dec;26(12):1797-1809. doi: 10.1038/s41431-018-0222-3. Epub 2018 Aug 10.

PMID:
30097616
20.

Precision gene editing technology and applications in nephrology.

WareJoncas Z, Campbell JM, Martínez-Gálvez G, Gendron WAC, Barry MA, Harris PC, Sussman CR, Ekker SC.

Nat Rev Nephrol. 2018 Nov;14(11):663-677. doi: 10.1038/s41581-018-0047-x. Review.

PMID:
30089813
21.

The time for next-generation molecular genetic diagnostics in nephrology is now!

Harris PC.

Kidney Int. 2018 Aug;94(2):237-239. doi: 10.1016/j.kint.2018.03.025.

PMID:
30031442
22.

Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, Senum SR, Hogan MC, El-Zoghby ZM, Kline TL, Harris PC, Czerwiec FS, Torres VE.

Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19. Erratum in: Clin J Am Soc Nephrol. 2019 Jun 7;14(6):910.

PMID:
30026287
23.

Polycystic Kidney Disease, Autosomal Dominant.

Harris PC, Torres VE.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2002 Jan 10 [updated 2018 Jul 19].

24.

The Underestimated Burden of Monogenic Diseases in Adult-Onset ESRD.

Cornec-Le Gall E, Harris PC.

J Am Soc Nephrol. 2018 Jun;29(6):1583-1584. doi: 10.1681/ASN.2018040441. Epub 2018 May 16. No abstract available.

25.

Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease.

Cornec-Le Gall E, Olson RJ, Besse W, Heyer CM, Gainullin VG, Smith JM, Audrézet MP, Hopp K, Porath B, Shi B, Baheti S, Senum SR, Arroyo J, Madsen CD, Férec C, Joly D, Jouret F, Fikri-Benbrahim O, Charasse C, Coulibaly JM, Yu AS, Khalili K, Pei Y, Somlo S, Le Meur Y, Torres VE; Genkyst Study Group; HALT Progression of Polycystic Kidney Disease Group; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease, Harris PC.

Am J Hum Genet. 2018 May 3;102(5):832-844. doi: 10.1016/j.ajhg.2018.03.013. Epub 2018 Apr 26.

26.

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?

Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE, The Halt Pkd Investigators.

Curr Hypertens Rev. 2018;14(1):39-47. doi: 10.2174/1573402114666180322110209.

27.

The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.

Cornec-Le Gall E, Chebib FT, Madsen CD, Senum SR, Heyer CM, Lanpher BC, Patterson MC, Albright RC, Yu AS, Torres VE; HALT Progression of Polycystic Kidney Disease Group Investigators, Harris PC.

Am J Kidney Dis. 2018 Aug;72(2):302-308. doi: 10.1053/j.ajkd.2017.11.015. Epub 2018 Feb 1.

PMID:
29395486
28.

MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.

de Stephanis L, Mangolini A, Servello M, Harris PC, Dell'Atti L, Pinton P, Aguiari G.

J Cell Physiol. 2018 Sep;233(9):6911-6924. doi: 10.1002/jcp.26473. Epub 2018 Mar 25.

PMID:
29323708
29.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT-PKD Trial Investigators.

Am J Kidney Dis. 2018 May;71(5):666-676. doi: 10.1053/j.ajkd.2017.10.023. Epub 2018 Jan 3.

30.

Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.

Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2018 Mar;93(3):691-699. doi: 10.1016/j.kint.2017.09.027. Epub 2017 Dec 28.

31.

Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies.

Chebib FT, Hogan MC, El-Zoghby ZM, Irazabal MV, Senum SR, Heyer CM, Madsen CD, Cornec-Le Gall E, Behfar A, Harris PC, Torres VE.

Kidney Int Rep. 2017 Jun 6;2(5):913-923. doi: 10.1016/j.ekir.2017.05.014. eCollection 2017 Sep.

32.

ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.

Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW.

Am J Kidney Dis. 2018 Feb;71(2):294-296. doi: 10.1053/j.ajkd.2017.09.008. Epub 2017 Dec 2. No abstract available.

33.

Primary Hyperoxaluria Type 1.

Milliner DS, Harris PC, Cogal AG, Lieske JC.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2002 Jun 19 [updated 2017 Nov 30].

34.

Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M.

J Am Soc Nephrol. 2018 Feb;29(2):571-578. doi: 10.1681/ASN.2017070819. Epub 2017 Nov 8.

35.

Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases.

Cornec-Le Gall E, Torres VE, Harris PC.

J Am Soc Nephrol. 2018 Jan;29(1):13-23. doi: 10.1681/ASN.2017050483. Epub 2017 Oct 16.

36.

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.

Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC.

Nephrol Dial Transplant. 2018 Apr 1;33(4):645-652. doi: 10.1093/ndt/gfx188.

37.

A potentially crucial role of the PKD1 C-terminal tail in renal prognosis.

Higashihara E, Horie S, Kinoshita M, Harris PC, Okegawa T, Tanbo M, Hara H, Yamaguchi T, Shigemori K, Kawano H, Miyazaki I, Kaname S, Nutahara K.

Clin Exp Nephrol. 2018 Apr;22(2):395-404. doi: 10.1007/s10157-017-1477-7. Epub 2017 Oct 5.

38.

Generation and phenotypic characterization of Pde1a mutant mice.

Wang X, Yamada S, LaRiviere WB, Ye H, Bakeberg JL, Irazabal MV, Chebib FT, van Deursen J, Harris PC, Sussman CR, Behfar A, Ward CJ, Torres VE.

PLoS One. 2017 Jul 27;12(7):e0181087. doi: 10.1371/journal.pone.0181087. eCollection 2017.

39.

Quantitative MRI of kidneys in renal disease.

Kline TL, Edwards ME, Garg I, Irazabal MV, Korfiatis P, Harris PC, King BF, Torres VE, Venkatesh SK, Erickson BJ.

Abdom Radiol (NY). 2018 Mar;43(3):629-638. doi: 10.1007/s00261-017-1236-y.

40.

The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.

Ye H, Wang X, Constans MM, Sussman CR, Chebib FT, Irazabal MV, Young WF Jr, Harris PC, Kirschner LS, Torres VE.

Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F677-F686. doi: 10.1152/ajprenal.00119.2017. Epub 2017 Jun 14.

41.

Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys.

Kline TL, Korfiatis P, Edwards ME, Blais JD, Czerwiec FS, Harris PC, King BF, Torres VE, Erickson BJ.

J Digit Imaging. 2017 Aug;30(4):442-448. doi: 10.1007/s10278-017-9978-1.

42.

Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.

Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ; CRISP Investigators.

Kidney Int. 2017 Nov;92(5):1206-1216. doi: 10.1016/j.kint.2017.03.026. Epub 2017 May 20.

43.

Polycystic Kidney Disease without an Apparent Family History.

Iliuta IA, Kalatharan V, Wang K, Cornec-Le Gall E, Conklin J, Pourafkari M, Ting R, Chen C, Borgo AC, He N, Song X, Heyer CM, Senum SR, Hwang YH, Paterson AD, Harris PC, Khalili K, Pei Y.

J Am Soc Nephrol. 2017 Sep;28(9):2768-2776. doi: 10.1681/ASN.2016090938. Epub 2017 May 18.

44.

Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.

Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE; HALT PKD Investigators.

Curr Hypertens Rev. 2017;13(2):109-120. doi: 10.2174/1573402113666170427142815.

45.

B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.

Holditch SJ, Schreiber CA, Harris PC, LaRusso NF, Ramirez-Alvarado M, Cataliotti A, Torres VE, Ikeda Y.

Kidney Int. 2017 Sep;92(3):657-668. doi: 10.1016/j.kint.2017.02.017. Epub 2017 Apr 14.

46.

PKD2-Related Autosomal Dominant Polycystic Kidney Disease: Prevalence, Clinical Presentation, Mutation Spectrum, and Prognosis.

Cornec-Le Gall E, Audrézet MP, Renaudineau E, Hourmant M, Charasse C, Michez E, Frouget T, Vigneau C, Dantal J, Siohan P, Longuet H, Gatault P, Ecotière L, Bridoux F, Mandart L, Hanrotel-Saliou C, Stanescu C, Depraetre P, Gie S, Massad M, Kersalé A, Séret G, Augusto JF, Saliou P, Maestri S, Chen JM, Harris PC, Férec C, Le Meur Y.

Am J Kidney Dis. 2017 Oct;70(4):476-485. doi: 10.1053/j.ajkd.2017.01.046. Epub 2017 Mar 27.

47.

microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism.

Hajarnis S, Lakhia R, Yheskel M, Williams D, Sorourian M, Liu X, Aboudehen K, Zhang S, Kersjes K, Galasso R, Li J, Kaimal V, Lockton S, Davis S, Flaten A, Johnson JA, Holland WL, Kusminski CM, Scherer PE, Harris PC, Trudel M, Wallace DP, Igarashi P, Lee EC, Androsavich JR, Patel V.

Nat Commun. 2017 Feb 16;8:14395. doi: 10.1038/ncomms14395.

48.

Distinguishing between Hepatic Inflammation and Fibrosis with MR Elastography.

Yin M, Glaser KJ, Manduca A, Mounajjed T, Malhi H, Simonetto DA, Wang R, Yang L, Mao SA, Glorioso JM, Elgilani FM, Ward CJ, Harris PC, Nyberg SL, Shah VH, Ehman RL.

Radiology. 2017 Sep;284(3):694-705. doi: 10.1148/radiol.2017160622. Epub 2017 Jan 27.

49.

Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression.

Streets AJ, Magayr TA, Huang L, Vergoz L, Rossetti S, Simms RJ, Harris PC, Peters DJ, Ong AC.

Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F577-F588. doi: 10.1152/ajprenal.00607.2016. Epub 2017 Jan 11.

50.

Digenic mutations of human OCRL paralogs in Dent's disease type 2 associated with Chiari I malformation.

Duran D, Jin SC, DeSpenza T Jr, Nelson-Williams C, Cogal AG, Abrash EW, Harris PC, Lieske JC, Shimshak SJ, Mane S, Bilguvar K, DiLuna ML, Günel M, Lifton RP, Kahle KT.

Hum Genome Var. 2016 Dec 8;3:16042. doi: 10.1038/hgv.2016.42. eCollection 2016.

Supplemental Content

Loading ...
Support Center